Altman Peter purchased $4K of BCDA
Altman Peter (President and CEO) purchased 5,000 shares of BioCardia, Inc. (BCDA) at $0.85 on 2026-06-09.
How this was made
The 30-second read
Why it matters
The only new information is the disclosed open-market purchase details (5,000 shares at $0.85, total $4,250) and post-transaction holdings (298,266 shares). No operational or financial guidance is provided.
Market read
Traders may note insider buying as a sentiment input, but the transaction size and lack of fundamental updates make it unlikely to drive a sustained repricing.
What to watch
The filing states no pre-arranged 10b5-1 plan, but it still does not disclose intent, timing constraints, or whether the purchase is part of a broader pattern.
Background
This is an SEC Form 4 insider transaction for BioCardia, Inc. (BCDA) by its President and CEO, Altman Peter.
Ticker impact
BioCardia CEO Altman Peter filed a Form 4 open-market purchase of 5,000 shares at $0.85 on 2026-06-09.
Likely minimal near-term price impact; any effect would be sentiment-driven and short-lived.
Form 4 insider purchases can be read as confidence, but the disclosed size ($4,250) is modest and the filing provides no new operating, financial, or regulatory information.
Market effects
No clear sector read-through from a small insider open-market purchase.
None indicated.
None indicated.
Counterpoint
Insider purchases can be routine (e.g., compensation-related liquidity needs) and do not necessarily reflect a change in business outlook.
Key entities
- issuerBioCardia, Inc.
Company whose Form 4 insider transaction was filed (BCDA).
- insiderAltman Peter
President and CEO who purchased 5,000 shares open-market on 2026-06-09.
